ReviewEuropean journal of neurology2022
The contribution of neuropathology to multiple sclerosis research.
Review in European journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Elevated Corpus Callosum T1rho Reflects Disease Burden and Structural Atrophy in Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2026Article
- A cause and protective treatment for acute and progressive disability and grey matter atrophy.Brain : a journal of neurology · 2026Review
- Network-based identification of regulatory hubs and therapeutic targets in multiple sclerosis: an integrated transcriptomic and molecular docking approach.Acta neurologica Belgica · 2026Article
- Microglia from patients with multiple sclerosis display a cell-autonomous immune activation state.Journal of neuroinflammation · 2025Article
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe Forms.International journal of molecular sciences · 2025Review
- Dark White Matter: Evidence of a Peri-Ictal MRI Sign from a Systematic Review.Journal of clinical medicine · 2025Review
- Multifaceted role of oxidative stress in neurological disorders.Molecular biology reports · 2025Review
- Brd4 expression in CD4 T cells and in microglia promotes neuroinflammation in experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2025Article
- Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS.European journal of neurology · 2025Article
- TIME: Tractography-Informed myelin estimation.NeuroImage. Clinical · 2025Article
- Oligodendrocyte and Myelin Pathophysiology in Multiple Sclerosis.Advances in neurobiology · 2025Review
- The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors.Frontiers in immunology · 2025Review
- De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.Current neurology and neuroscience reports · 2024Review
- Fluid biomarkers in multiple sclerosis: from current to future applications.The Lancet regional health. Europe · 2024Review
- Forensic neuropathology in the past decade: a scoping literature review.Forensic science, medicine, and pathology · 2024Article
- Early regional cerebral grey matter damage predicts long-term cognitive impairment phenotypes in multiple sclerosis: a 20-year study.Brain communications · 2024Article
- Cultured lymphocytes' mitochondrial genome integrity is not altered by cladribine.Clinical and experimental immunology · 2023Article
- Influenza A virus infection disrupts oligodendrocyte homeostasis and alters the myelin lipidome in the adult mouse.Journal of neuroinflammation · 2023Article
- Implications of immunometabolism for smouldering MS pathology and therapy.Nature reviews. Neurology · 2023Review
- Roles and regulation of microglia activity in multiple sclerosis: insights from animal models.Nature reviews. Neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeNeuropathology plays a major role in deciphering disease mechanisms in multiple sclerosis (MS). This review article describes recent advances in neuropathological research related to inflammatory demyelinating diseases.
methodsA retrospective review of neuropathological studies published during the last two decades was conducted.
resultsThe importance of neuropathology is generally seen in its contribution to the diagnosis of diseases of the nervous system and, in particular, in neuro-oncology. However, when it also includes analysis of the global three-dimensional extension of brain damage and the temporal sequence of lesion evolution and relates this to molecular changes in the lesions, it offers the potential to decipher disease pathogenesis and to contribute to the development of effective and causative treatments. In MS research, neuropathology has been essential in discriminating the disease from other inflammatory autoimmune or demyelinating diseases, such as neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). It defined the hallmark of chronic progressive disease in MS patients as slowly expanding tissue damage, which occurs not only within and around lesions but also in the normal appearing white and gray matter. It showed that these changes occur in the course of a tissue-resident immune response within the central nervous system, involving tissue-resident effector memory cells and plasma cells. Molecular studies in neuropathologically defined micro-dissected MS lesions identified a cascade of oxidative injury, mitochondrial damage and subsequent virtual hypoxia as a major pathway of tissue injury in MS.
conclusionsThe results of these studies were highly relevant for the identification of potential therapeutic targets in MS patients and the design of pivotal clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.